Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer

Inclusion Criteria: * Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent * Subject has histologically or cytologically proven endometrial cancer * Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician * Naive to chemotherapy * Women of child-bearing potential must have a negative pregnancy test (urine). Female patients are considered of child-bearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Patients are considered to not be of child-bearing potential if they have a history of tubal ligation or hysterectomy or are post-menopausal with a minimum of 1 year without menses. Patients of child-bearing potential must agree to adequate birth control if conception is possible during the study and for 6 months after the last dose; in this case, patients must take a monthly pregnancy test for the duration of the study Exclusion Criteria: * They will experience emesis within the 24 hours before receipt of 1 course of chemotherapy * will be scheduled to radiation therapy to the abdomen or pelvis within 1 week before day 1 or between day 1 and 5 * Will be scheduled to undergo bone marrow or stem-cell transplant * Chronic systemic corticosteroid use * Brain metastasis * Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder * History or predisposition to cardiac conduction abnormalities, torsade des pointes or severe cardiovascular diseases * Subject is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study treatment * They have any known hypersensitivity or contraindication to the components of the study drugs (hypersensitivity to the active substance or to any of the excipients contained in the product, as listed in the relevant section of the summary of product characteristics)